Compare Lupin Ltd with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs TORRENT PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN TORRENT PHARMA LUPIN/
TORRENT PHARMA
 
P/E (TTM) x 108.2 54.3 199.1% View Chart
P/BV x 2.5 6.5 37.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 LUPIN   TORRENT PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
TORRENT PHARMA
Mar-18
LUPIN/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,550 63.6%   
Low Rs7201,144 63.0%   
Sales per share (Unadj.) Rs369.5354.7 104.2%  
Earnings per share (Unadj.) Rs13.440.1 33.4%  
Cash flow per share (Unadj.) Rs37.464.2 58.2%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs303.7273.1 111.2%  
Shares outstanding (eoy) m452.49169.22 267.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.33.8 60.8%   
Avg P/E ratio x63.633.6 189.4%  
P/CF ratio (eoy) x22.821.0 108.8%  
Price / Book Value ratio x2.84.9 57.0%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m386,064227,897 169.4%   
No. of employees `00017.714.7 120.3%   
Total wages/salary Rs m31,51311,353 277.6%   
Avg. sales/employee Rs Th9,453.84,083.0 231.5%   
Avg. wages/employee Rs Th1,782.0772.3 230.7%   
Avg. net profit/employee Rs Th343.0461.3 74.4%   
INCOME DATA
Net Sales Rs m167,18260,021 278.5%  
Other income Rs m3,6402,988 121.8%   
Total revenues Rs m170,82263,009 271.1%   
Gross profit Rs m28,82213,493 213.6%  
Depreciation Rs m10,8504,086 265.5%   
Interest Rs m3,0783,085 99.8%   
Profit before tax Rs m18,5349,310 199.1%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0172,529 356.6%   
Profit after tax Rs m6,0666,781 89.4%  
Gross profit margin %17.222.5 76.7%  
Effective tax rate %48.727.2 179.1%   
Net profit margin %3.611.3 32.1%  
BALANCE SHEET DATA
Current assets Rs m138,53652,623 263.3%   
Current liabilities Rs m61,29952,022 117.8%   
Net working cap to sales %46.21.0 4,610.0%  
Current ratio x2.31.0 223.4%  
Inventory Days Days84120 70.1%  
Debtors Days Days11276 147.5%  
Net fixed assets Rs m127,51685,016 150.0%   
Share capital Rs m905846 106.9%   
"Free" reserves Rs m136,51745,376 300.9%   
Net worth Rs m137,42246,222 297.3%   
Long term debt Rs m66,41741,115 161.5%   
Total assets Rs m279,494142,432 196.2%  
Interest coverage x7.04.0 174.7%   
Debt to equity ratio x0.50.9 54.3%  
Sales to assets ratio x0.60.4 141.9%   
Return on assets %3.36.9 47.2%  
Return on equity %4.414.7 30.1%  
Return on capital %8.914.2 62.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41414,580 407.5%   
Fx outflow Rs m22,2823,600 619.0%   
Net fx Rs m37,13210,980 338.2%   
CASH FLOW
From Operations Rs m16,6608,942 186.3%  
From Investments Rs m-32,825-47,070 69.7%  
From Financial Activity Rs m7,44134,174 21.8%  
Net Cashflow Rs m-8,724-3,655 238.7%  

Share Holding

Indian Promoters % 46.6 71.5 65.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 7.0 161.0%  
FIIs % 31.9 12.6 253.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.8 114.8%  
Shareholders   98,259 26,511 370.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   ORCHID PHARMA LTD  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  CIPLA  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Nov 18, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS